Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030
GLP-1 weight loss drugs are propelling profits for some drugmakers like Eli Lilly.
Investing $100 monthly in Eli Lilly (LLY) stock could potentially be worth $8,000 by 2030, according to an educated estimate. While no one can predict exact stock performance, Lilly has demonstrated strong growth rates, notably due to blockbuster GLP-1 weight-loss drugs like Mounjaro and Zepbound. The global market for GLP-1 drugs is projected to nearly double between 2025 and 2035, reaching $190 billion.
However, it's important to consider competition from companies like Novo Nordisk's Ozempic and Wegovy. For a conservative estimation, a 25% annual growth rate is more realistic. With $1,200 annually invested, the stake could be worth around $8,000 by the end of four years. Despite Lilly's valuation being somewhat elevated, its recent price-to-sales ratio of 14.4 and price-to-earnings ratio of 43 suggest a potential pullback could occur, affecting growth projections. As always, thorough research is recommended before making investment decisions.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
